Division of Cancer Prevention and Control, College of Medicine, The Ohio State University, Suite 525, 1590 North High Street, Columbus, Ohio 43201, USA.
Cancer Epidemiol Biomarkers Prev. 2012 Dec;21(12):2220-30. doi: 10.1158/1055-9965.EPI-12-0850. Epub 2012 Nov 7.
Appalachia is a geographic region with high cervical cancer incidence and mortality rates, yet little is known about human papillomavirus (HPV) vaccination in this region. We determined HPV vaccine coverage among adolescent females from Appalachia, made comparisons to non-Appalachian females, and examined how coverage differs across subregions within Appalachia.
We analyzed data from the National Immunization Survey-Teen 2008-2010 for adolescent females ages 13-17 (n = 1,951, Appalachian females and n = 25,468, non-Appalachian females). We examined HPV vaccine initiation (receipt of at least one dose), completion (receipt of at least three doses), and follow-through (completion among initiators). Analyses used weighted logistic regression.
HPV vaccine initiation [Appalachian = 40.8% vs. non-Appalachian = 43.6%; OR, 0.92; 95% confidence interval (CI), 0.79-1.07] and completion (Appalachian = 27.7% vs. non-Appalachian = 25.3%; OR, 1.12; 95% CI, 0.95-1.32) were similar between Appalachian and non-Appalachian females. HPV vaccine follow-through was higher among Appalachian females than non-Appalachian females (67.8% vs. 58.1%; OR, 1.36; 95% CI, 1.07-1.72). Vaccination outcomes tended to be higher in the Northern (completion and follow-through) and South Central (follow-through) subregions of Appalachia compared with non-Appalachian United States. Conversely, vaccination outcomes tended to be lower in the Central (initiation and completion) and Southern (initiation and completion) subregions.
In general, HPV vaccination in Appalachia is mostly similar to the rest of the United States. However, vaccination is lagging in regions of Appalachia where cervical cancer incidence and mortality rates are highest.
Current cervical cancer disparities could potentially worsen if HPV vaccine coverage is not improved in regions of Appalachia with low HPV vaccine coverage.
阿巴拉契亚地区的宫颈癌发病率和死亡率都很高,但人们对该地区的人乳头瘤病毒(HPV)疫苗接种情况知之甚少。我们确定了阿巴拉契亚地区青少年女性的 HPV 疫苗接种率,并与非阿巴拉契亚地区的女性进行了比较,还研究了阿巴拉契亚地区内各子区域之间的接种率差异。
我们分析了 2008-2010 年全国免疫调查-青少年的数据,该数据包括年龄在 13-17 岁的 1951 名阿巴拉契亚地区女性和 25468 名非阿巴拉契亚地区女性。我们检查了 HPV 疫苗接种的启动(至少接种一剂)、完成(至少接种三剂)和持续接种(接种启动者完成接种)情况。分析使用了加权逻辑回归。
HPV 疫苗接种启动率[阿巴拉契亚地区=40.8%,非阿巴拉契亚地区=43.6%;OR,0.92;95%置信区间(CI),0.79-1.07]和完成率(阿巴拉契亚地区=27.7%,非阿巴拉契亚地区=25.3%;OR,1.12;95%CI,0.95-1.32)在阿巴拉契亚地区和非阿巴拉契亚地区女性之间相似。阿巴拉契亚地区女性的 HPV 疫苗持续接种率高于非阿巴拉契亚地区女性(67.8% vs. 58.1%;OR,1.36;95%CI,1.07-1.72)。与非阿巴拉契亚美国相比,阿巴拉契亚地区的北部(完成和持续接种)和中南部(持续接种)子区域的疫苗接种结果往往更高。相反,阿巴拉契亚地区的中部(启动和完成)和南部(启动和完成)子区域的疫苗接种结果往往更低。
总体而言,阿巴拉契亚地区的 HPV 疫苗接种情况与美国其他地区基本相似。然而,在宫颈癌发病率和死亡率最高的阿巴拉契亚地区,疫苗接种情况滞后。
如果不提高 HPV 疫苗接种率较低的阿巴拉契亚地区的疫苗接种率,当前的宫颈癌差异可能会进一步恶化。